An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essent

• Status: Terminated
• Trial end date: 2006-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Hydrochlorothiazide; Losartan

Criteria

Inclusion Criteria:

• Patient treated with valsartan 80mg or irbesartan 150mg or vandesartan 8mg for at least 4 weeks prior to visit 1

• Patient with systolic blood pressure between 140 to 159 mmhg and diastolic pressure between 90 to 99mmhg taken at visit 1

Exclusion Criteria:

• History of angina pectoris that has not been stabilized in the past 6 weeks

• History of clinically significant abnormal lab results or diseases

• Myocardial infarction within the past 6 months

• Stroke in the past 6 months